CRVS (Corvus Pharmaceuticals) Total Equity : $32.57 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Total Equity?

Corvus Pharmaceuticals's total equity for the quarter that ended in Dec. 2024 was $32.57 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Corvus Pharmaceuticals Total Equity Historical Data

The historical data trend for Corvus Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Total Equity Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Equity

Get a 7-Day Free Trial

72.15

97.16

56.12

38.68

32.57

Corvus Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Equity	Get a 7-Day Free Trial															38.68	33.36	51.23	12.41	32.57

Corvus Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Corvus Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	68.907	-	36.339
	=	32.57

Corvus Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	68.907	-	36.339
	=	32.57

Corvus Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

C17:Germany

Address

863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Executives

William Benton Jones	officer: See Remarks	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Miller Richard A Md	director, officer: President and CEO	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
Leiv Lea	officer: Chief Financial Officer	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell	director	1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher	officer: Chief Medical Officer	863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould	director, 10 percent owner	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy	officer: EVP Discovery Research	CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt	officer: SVP, Chief Business Officer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner	officer: V.P., Chemistry Research	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010